Holen Sie sich die Stockscreener-App
14.94
0.10%
-0.015
Schlusskurs vom Vortag:
$14.95
Offen:
$14.74
24-Stunden-Volumen:
2.05M
Relative Volume:
0.95
Marktkapitalisierung:
$2.28B
Einnahmen:
$205.22M
Nettoeinkommen (Verlust:
$-121.24M
KGV:
-18.35
EPS:
-0.8141
Netto-Cashflow:
$-82.81M
1W Leistung:
-20.09%
1M Leistung:
+0.98%
6M Leistung:
+42.92%
1J Leistung:
+131.91%
1-Tages-Spanne:
$14.69
$15.62
1-Wochen-Bereich:
$14.58
$18.87
52-Wochen-Spanne:
$5.805
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Vergleichen Sie ADPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
14.92 | 2.28B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.76 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.23 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.46 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.54 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.12 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Adaptive Biotechnologies chief commercial officer sells $212k in stock - Investing.com
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake - Yahoo Finance
Adaptive Biotechnologies CEO Chad M Robins Sells $3M in Company Shares - StocksToTrade
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at ASH Meeting - GuruFocus
Adaptive Biotechnologies Stock Declines After Insider Sale - timothysykes.com
December Disappointments: 10 Big Names Troubled Early - Insider Monkey
Adaptive Biotechnologies’ Stock Faces Turmoil Amid Insider Selling - StocksToTrade
Adaptive Biotechnologies Corporation Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting - marketscreener.com
Adaptive Biotechnologies Highlights Expanded Clinical Use of clonoSEQ® Test at 67th ASH Annual Meeting - Quiver Quantitative
Adaptive Biotechnologies (Nasdaq: ADPT) shows clonoSEQ MRD guiding blood cancer care at ASH 2025 - Stock Titan
Insider Sell: Harlan Robins Sells 37,212 Shares of Adaptive Biot - GuruFocus
Adaptive Biotechnologies CSO Robins sells $672,515 in ADPT stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CSO Robins sells $672,515 in ADPT stock - Investing.com
Adaptive Biotechnologies Exec Sells Over $670K in Company Stock - TradingView
Officer Robins Sells 37,212 ($672.5K) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Adaptive Biotechnologies (ADPT) Is Down 11.2% After Earnings Beat And CFO Share SaleHas The Bull Case Changed? - simplywall.st
Will Adaptive Biotechnologies Corporation stock beat EPS estimatesDollar Strength & AI Enhanced Trading Alerts - Newser
Officer Robins Files To Sell 10,000 Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Will Adaptive Biotechnologies Corporation (1HM) stock draw ESG focused funds2025 Earnings Surprises & Stock Portfolio Risk Control - Newser
Will Adaptive Biotechnologies Corporation (1HM) stock sustain uptrend momentum2025 Dividend Review & Real-Time Volume Analysis Alerts - Newser
Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback - Yahoo! Finance Canada
Ready to Jump After Recent Trade: Adaptive Biotechnologies Corp (ADPT) - Setenews
Adaptive biotechnologies CFO Piskel sells $3.17 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $2,367,462.12 in Stock - MarketBeat
ADPT FinancialsIncome Statement - Quiver Quantitative
Adaptive biotechnologies CFO Piskel sells $3.17 million in stock - Investing.com
Adaptive Biotechnologies CFO Kyle Piskel Sells Over 162K Shares - TradingView
CFO Piskel Sells 162,820 ($3.2M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Adaptive Biotechnologies (ADPT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ameritas Investment Partners Inc. Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - Defense World
Chad Robins Sells 160,734 Shares of Adaptive Biotechnologies Cor - GuruFocus
Adaptive Biotechnologies CEO Robins sells $3.07 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CEO Robins sells $3.07 million in stock - Investing.com
Adaptive Biotechnologies CEO Sells Shares Worth Over $3 Million - TradingView
Chmn Robins Sells 160,734 ($3.1M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Chmn Robins Files To Sell 124,998 Of Adaptive Biotechnologies Corp [ADPT] - TradingView
CFO Piskel Files To Sell 162,820 Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Geode Capital Management LLC Has $37.46 Million Position in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Street Watch: Why Adaptive Biotechnologies Corporation stock remains undervaluedGlobal Markets & Weekly High Return Opportunities - BỘ NỘI VỤ
Its Stock Has Paid Off Big Time For Adaptive Biotechnologies Corp - Setenews
Sharon Benzeno Sells 308,477 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock - MarketBeat
Adaptive Biotechnologies’ Benzeno sells $10.1m in shares By Investing.com - Investing.com India
Adaptive Biotechnologies’ Benzeno sells $10.1m in shares - Investing.com
Adaptive Biotechnologies CCO reports major option exercises, sales - Stock Titan
Officer Benzeno Sells 606,402 ($10.1M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test at Hemat - GuruFocus
Adaptive Biotechnologies' clonoSEQ® Test Featured in 89 Abstracts at ASH Annual Meeting 2025 - Quiver Quantitative
Adaptive Biotechnologies (ADPT) Highlights clonoSEQ in 89 ASH Abstracts, 36 Orals - Stock Titan
Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why - Finviz
Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here’s Why - Insider Monkey
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):